We read with great interest the recently published article by Zachou et al., in which they investigated the possible application of serum cartilage oligomeric matrix protein (COMP) levels as a novel non-invasive marker of fibrosis in patients with chronic viral hepatitis (CVH) and compared this marker with histology, transient elastography (TE), APRI and FIB-4 for the estimation of fibrosis stage [1]. They concluded that serum COMP levels performed as well as TE, APRI and FIB-4 score in detecting cirrhosis in CVH patients [1].
